Registry of Toxic Effects of Chemical Substances (RTECS)
ShareCompartir
Hydrogen peroxide, 90%
RTECS #
MX0900000CAS #
7722-84-1Updated
December 2013Molecular Weight
34.02Molecular Formula
H2O2Synonyms
AlboneDihydrogen dioxide
Hioxyl
Hydrogen dioxide
Hydrogen peroxide
Hydrogen peroxide (ACGIH:OSHA)
Hydroperoxide
Inhibine
Oxydol
Perhydrol
Perone
Perossido di idrogeno (Italian)
Peroxan
Peroxide
Peroxyde d'hydrogene (French)
Superoxol
T-Stuff
Wasserstoffperoxid (German)
Waterstofperoxyde (Dutch)
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 1 mg | severe | JTPAE7 29,308,2001 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | Ascites tumor/mouse | 10 mmol/L | MUREAV 4,385,1967 |
| Cytogenetic Analysis | embryo/mouse | 10 µmol/L | IDZAAW 56,1,1981 |
| Cytogenetic Analysis | ovary/hamster | 1 mmol/L | CALEDQ 5,199,1978 |
| Cytogenetic Analysis | lung/hamster | 100 µmol/L | IDZAAW 56,1,1981 |
| Cytogenetic Analysis | embryo/hamster | 100 µmol/L | IDZAAW 56,1,1981 |
| Cytogenetic Analysis | fibroblast/hamster | 250 mg/L | ESKHA5 (96),55,1978 |
| Cytogenetic Analysis | other cell types/human | 1.5 mg/L/4H | MUREAV 578,100,2005 |
| Cytogenetic Analysis | ovary/hamster | 0.3 mmol/L/1H | MUREAV 649,114,2008 |
| Cytogenetic Analysis | lymphocyte/human | 30 µmol/L/30M | MUREAV 559,97,2004 |
| Cytogenetic Analysis | lymphocyte/human | 10 µmol/L/2H | MUREAV 669,155,2009 |
| DNA adduct | other cell types/human | 50 µmol/L/4H | CNREA8 69,3052,2009 |
| DNA adduct | embryo/hamster | 0.09 µmol/L/1H | MUREAV 563,35,2004 |
| DNA adduct | lymphocyte/human | 25 µmol/L/1H | MUREAV 582,155,2005 |
| DNA Damage | liver/mouse | 50 µmol/L/1H | TOXID9 44,153,2005 |
| DNA Damage | fibroblast/human | 50 mmol/L/1H | TOLED5 147,35,2004 |
| DNA Damage | lymphocyte/human | 100 µmol/L/3M | MUREAV 587,52,2005 |
| DNA Damage | other cell types/human | 100 µmol/L/3M | MUREAV 587,52,2005 |
| DNA Damage | embryo/salmon | 5 µmol/L/1H | MUREAV 563,89,2004 |
| DNA Damage | other cell types/mouse | 200 µmol/L/1H (-enzymatic activation step) | MUREAV 541,9,2003 |
| DNA Damage | ovary/hamster | 200 µmol/L/5M | MUREAV 560,41,2004 |
| DNA Damage | mammary gland/human | 9.8 mg/L/24H (-enzymatic activation step) | MUREAV 588,47,2005 |
| DNA Damage | other cell types/human | 18.75 µmol/L | TOXID9 66,307,2002 |
| DNA Damage | fibroblast/mouse | 500 µmol/L/1H | FCTOD7 44,261,2006 |
| DNA Damage | other cell types/human | 200 µmol/L/60M | MUREAV 577S,1,2005 |
| DNA Damage | other cell types/human | 2000 µmol/L/3H (-enzymatic activation step) | MUTAEX 20,193,2005 |
| DNA Damage | other cell types/woman | 1 mmol/L/1H | TXCYAC 222,71,2006 |
| DNA Damage | other cell types/rat | 75 µmol/L/5M | TOLED5 159,212,2005 |
| DNA Damage | lymphocyte/rat | 50 µmol/L/5M | TOLED5 164,54,2006 |
| DNA Damage | testis/rat | 50 µmol/L/5M | TOLED5 164,54,2006 |
| DNA Damage | lung/rat | 50 µmol/L/5M | TOLED5 164,54,2006 |
| DNA Damage | liver/rat | 50 µmol/L/5M | TOLED5 164,54,2006 |
| DNA Damage | fibroblast/human | 100 µmol/L/20M | MUREAV 546,93,2004 |
| DNA Damage | liver/human | 56 µmol/L/10M | MUREAV 657,133,2008 |
| DNA Damage | other cell types/human | 25 µmol/L/30M | TOLED5 170,57,2007 |
| DNA Damage | lung/hamster | 150 µmol/L/1H | MUREAV 631,44,2007 |
| DNA Damage | other cell types/rat | 100 µmol/L/10M | MUREAV 634,51,2007 |
| DNA Damage | other cell types/rat | 1 mmol/L/30M | NRTXDN 28,886,2007 |
| DNA Damage | other cell types/rat | 0.1 mmol/L/6H | NRTXDN 28,886,2007 |
| DNA Damage | other cell types/mouse | 50 µmol/L | MUTAEX 20,469,2005 |
| DNA Damage | lymphocyte/human | 5.0 mg/L/48H | MUREAV 607,160,2006 |
| DNA Damage | other cell types/hamster | 40 µmol/L/1H | MUREAV 559,39,2004 |
| DNA Damage | lymphocyte/rat | 50 µmol/L/10M | MUREAV 564,75,2004 |
| DNA Damage | mammary gland/human | 100 µmol/L/5M | TXAPA9 232,169,2008 |
| DNA Damage | lung/human | 0.05 mmol/L/5M | TOXID9 -,221,2009 |
| DNA Damage | lymphocyte/human | 1 µmol/L/2H | TOSCF2 72,283,2003 |
| DNA Damage | fibroblast/human | 250 µmol/L/5M | MUREAV 677,46,2009 |
| DNA Damage | lymphocyte/human | 25 µmol/L/30M (-enzymatic activation step) | FCTOD7 48,320,2010 |
| DNA Damage | lymphocyte/human | 5 µmol/L/10M | MUREAV 652,46,2008 |
| DNA Damage | fibroblast/human | 20 µmol/L/15M | MUREAV 701,103,2010 |
| DNA Damage | lymphocyte/human | 20 µmol/L/15M | MUREAV 701,103,2010 |
| DNA Damage | fibroblast/hamster | 40 µmol/L/15M | MUREAV 701,103,2010 |
| DNA Damage | liver/human | 40 µmol/L/15M | MUREAV 701,103,2010 |
| DNA Damage | HeLa cell/human | 40 µmol/L/15M | MUREAV 701,103,2010 |
| DNA Damage | other cell types/rat | 100 µmol/L/20M | NRSCDN 151,518,2008 |
| DNA Damage | leukocyte/human | 200 µmol/L/5M | MUREAV 718,56,2011 |
| DNA Damage | other cell types/mouse | 190 µmol/L/4H | MUREAV 678,123,2009 |
| DNA Damage | ovary/hamster | 20 µmol/L | MUREAV 299,95,1993 |
| DNA Damage | lung/hamster | 353 µmol/L | NATUAS 282,318,1979 |
| DNA Damage | other cell types/cattle | 25 µmol/L | MUREAV 240,35,1990 |
| DNA Damage | lymphocyte/mammal (species unspecified) | 600 µmol/L | DECRDP 8,1,1982 |
| DNA Damage | lung/human | 300 µmol/L/1H | MUREAV 515,99,2002 |
| DNA Damage | liver/rat | 300 µmol/L/1H | MUREAV 515,99,2002 |
| DNA Damage | other cell types/human | 100 µmol/L/3H | MUTAEX 16,439,2001 |
| DNA Damage | other cell types/rat | 10 µmol/L/24H | ATSUDG 75,243,2001 |
| DNA Damage | other cell types/human | 10 µmol/L/15M | MUREAV 519,151,2002 |
| DNA Damage | lung/hamster | 200 µmol/L/24H | ARTODN 75,604,2001 |
| DNA Damage | lymphocyte/human | 0.01 mmol/L/1H | MUREAV 535,25,2003 |
| DNA Damage | other cell types/human | 0.01 mmol/L/1H | MUREAV 535,25,2003 |
| DNA Damage | other cell types/mouse | 0.01 mmol/L/1H | MUREAV 535,25,2003 |
| DNA Damage | lymphocyte/human | 0.01 mmol/L/30M | TCMUD8 20,11,2000 |
| DNA Damage | /Escherichia coli | 0.001 µmol/plate/2H | MUREAV 535,171,2003 |
| DNA Damage | other cell types/other fish | 0.001 mmol/L/5M | MUREAV 534,165,2003 |
| DNA Damage | other cell types/non-mammalian species | 0.04 mmol/L/1H | MUREAV 539,19,2003 |
| DNA Damage | sperm/human | 80 µmol/L/1H | MUREAV 544,173,2003 |
| DNA Damage | fibroblast/mouse | 25 µmol/L/15M | MUREAV 531,165,2003 |
| DNA Damage | other cell types/non-mammalian species | 44 µmol/L/20M | MUREAV 542,15,2003 |
| DNA Damage | other cell types/rat | 200 µmol/L | CRNGDP 20,629,1999 |
| DNA Damage | other cell types/mouse | 100 µmol/L | JCINAO 77,1312,1986 |
| DNA Damage | other cell types/mouse | 1 µmol/L | CRNGDP 4,1507,1983 |
| DNA Damage | lymphocyte/mouse | 2 mmol/L | MUREAV 203,155,1988 |
| DNA Damage | fibroblast/human | 28 µmol/L | BBACAQ 781,56,1984 |
| DNA Damage | leukocyte/human | 20 µmol/L | MUREAV 265,255,1992 |
| DNA Damage | /Bacillus subtilis | 50 mmol/L | BBACAQ 155,476,1968 |
| DNA Damage | /Other microorganisms | 1 mmol/L | MUREAV 368,235,1996 |
| DNA Damage | /Neurospora crassa | 50 µmol/L | MUREAV 405,29,1998 |
| DNA Damage | lymphocyte/human | 0.3 mg/L/1H | FCTOD7 49,763,2011 |
| DNA Damage | ovary/hamster | 200 µmol/L/1H | FCTOD7 49,385,2011 |
| DNA Damage | other cell types/human | 10 µmol/L/5M | MUREAV 749,70,2012 |
| DNA Damage | fibroblast/hamster | 100 µmol/L/30M | FCTOD7 50,1796,2012 |
| DNA Damage | HeLa cell/human | 300 µmol/L/1H | FCTOD7 50,3475,2012 |
| DNA Damage | other cell types/mouse | 0.25 mmol/L/5M | FCTOD7 50,2275,2012 |
| DNA Damage | lymphocyte/human | 10 µmol/L | FCTOD7 49,2947,2011 |
| DNA Damage | fibroblast/mouse | 10 µmol/L/10M | MUREAV 745-746,16,2013 |
| DNA Damage | other cell types/human | 1 µmol/L/12H | MUTAEX 28,515,2013 |
| DNA Damage | lung/human | 10 mmol/L/24H | HETOEA 28,339,2009 |
| DNA Damage | liver/human | 1 mmol/l/48H | MUREAV 696,21,2010 |
| DNA Damage | liver/human | 0.316 mmol/l/48H | MUREAV 696,21,2010 |
| DNA Damage | mammary gland/human | 50 µmol/L/10M | FCTOD7 48,1092,2010 |
| DNA Damage | other cell types/human | 50 µmol/L/10M | FCTOD7 48,1092,2010 |
| DNA Damage | /Saccharomyes cerevisiae | 10 mmol/L/20M | FCTOD7 49,1361,2011 |
| DNA Damage | leukocyte/human | 300 µmol/L/2H | MUREAV 726,146,2011 |
| DNA Damage | oral/Drosophila melanogaster | 50 µmol/L/24H- intermittent | MUREAV 726,222,2011 |
| DNA Damage | lymphocyte/human | 10 µmol/L (+/-enzymatic activation step) | MUREAV 743,25,2012 |
| DNA Damage | sperm/human | 10 µmol/L (+/-enzymatic activation step) | MUREAV 743,25,2012 |
| DNA Damage | other cell types/mouse | 200 µmol/L/30M | TIHEEC 25,5,2009 |
| DNA Damage | lymphocyte/human | 70 µmol/L/40M | MUREAV 724,41,2011 |
| DNA Damage | other cell types/human | 70 µmol/L/60M | MUREAV 724,41,2011 |
| DNA Damage | lymphocyte/human | 10 µmol/L/5M | MUREAV 748,60,2012 |
| DNA inhibition | other cell types/human | 1200 µmol/L | CNREA8 45,2522,1985 |
| DNA inhibition | other cell types/mouse | 40 µmol/L | JCINAO 77,1312,1986 |
| DNA inhibition | fibroblast/human | 1 mg/L | CRNGDP 4,1317,1983 |
| DNA repair | /Salmonella typhimurium | 2 mmol/L/60M | MUREAV 502,11,2002 |
| DNA repair | other cell types/human | 10 mmol/L/10M | MUREAV 537,1,2003 |
| DNA repair | fibroblast/human | 20 µmol/L/1H | MUREAV 513,159,2002 |
| DNA repair | /Escherichia coli | 14630 µg/well/16H | CBINA8 15,219,1976 |
| DNA repair | other cell types/human | 10 µmol/L/20M | MUREAV 577S,1,2005 |
| DNA repair | other cell types/human | 1 µmol/L/12H | MUTAEX 28,515,2013 |
| DNA repair | lymphocyte/human | 100 µmol/L | MUREAV 724,46,2011 |
| DNA repair | fibroblast/mouse | 5 µmol/L/6D | MUREAV 745-746,16,2013 |
| gene conversion and mitotic recombination | other cell types/Drosophila melanogaster | 120 mmol/L | FCTOD7 50,1384,2012 |
| gene conversion and mitotic recombination | /Saccharomyes cerevisiae | 5 pph | AGACBH 4,286,1974 |
| micronucleus test | other cell types/human | 10 µmol/L | MUREAV 577S,1,2005 |
| micronucleus test | ovary/hamster | 500 µmol/L/24H (-enzymatic activation step) | MUREAV 630,1,2007 |
| micronucleus test | embryo/hamster | 5 mg/L/4H (-enzymatic activation step) | MUREAV 561,153,2004 |
| micronucleus test | lymphocyte/human | 3.4 mg/L/24H | EMMUEG 43,45,2004 |
| micronucleus test | other cell types/mouse | 20 µmol/L/4H | MUREAV 678,123,2009 |
| micronucleus test | lymphocyte/human | 30 µmol/L/30M | MUREAV 559,97,2004 |
| micronucleus test | lung/hamster | 150 µmol/L/1H | MUREAV 631,44,2007 |
| micronucleus test | lymphocyte/pig | 10 µmol/L/72H | MUREAV 653,124,2008 |
| morphological transform | liver/rat | 100 µmol/L/7W | MOCAE8 30,209,2001 |
| morphological transform | embryo/mouse | 20 µmol/L | CRNGDP 10,1055,1989 |
| morphological transform | embryo/hamster | 2500 µg/L | MUREAV 356,85,1996 |
| mutation in mammalian somatic cells | lung/hamster | 10 µmol/L | CRNGDP 10,1055,1989 |
| mutation in mammalian somatic cells | kidney/monkey | 7 mmol/L | CRNGDP 11,283,1990 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 18600 nmol/L | MUTAEX 3,193,1988 |
| mutation in microorganisms | /Schizosaccharomyces pombe | 2820 mmol/L (-enzymatic activation step) | ADWMAX -,193,1962 |
| mutation in microorganisms | /Bacillus subtilis | 5 ppm (-enzymatic activation step) | MUREAV 95,191,1982 |
| mutation in microorganisms | /Salmonella typhimurium | 6 µg/plate (-enzymatic activation step) | ABCHA6 44,1989,1980 |
| mutation in microorganisms | /Escherichia coli | 5 pph (-enzymatic activation step) | AGACBH 4,286,1974 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 10 mg/L (-enzymatic activation step) | MUREAV 33,147,1975 |
| mutation in microorganisms | /Neurospora crassa | 210 mmol/L/30M (-enzymatic activation step) | PNASA6 35,581,1949 |
| mutation in microorganisms | /Haemophilus influenzae | 800 µmol/L (-enzymatic activation step) | MUREAV 30,9,1975 |
| mutation in microorganisms | /Other microorganisms | 6 ppm/1H-continuous (-enzymatic activation step) | JOBAAY 54,767,1947 |
| mutation in microorganisms | /Other microorganisms | 6 ppm (-enzymatic activation step) | POASAD 34,114,1953 |
| mutation in microorganisms | /Bacillus subtilis | 5 pph/15M | MUREAV 503,77,2002 |
| mutation in microorganisms | /Salmonella typhimurium | 1.87 mg/plate/30M | MUREAV 535,171,2003 |
| mutation in microorganisms | /Salmonella typhimurium | 25 µg/plate/48H (+/-enzymatic activation step) | MUREAV 539,29,2003 |
| mutation in microorganisms | /Escherichia coli | 100 µg/plate/48H (+/-enzymatic activation step) | MUREAV 539,29,2003 |
| mutation in microorganisms | /Salmonella typhimurium | 34000 ng/plate/72H | MUREAV 542,49,2003 |
| mutation in microorganisms | /Salmonella typhimurium | 500 µg/plate/66H (-enzymatic activation step) | EMMUEG 40,63,2002 |
| mutation in microorganisms | /Salmonella typhimurium | 51 µg/plate/72H (-enzymatic activation step) | MUTAEX 15,495,2000 |
| mutation in microorganisms | /Salmonella typhimurium | 20 µL/plate/30M | DCTODJ 27,157,2004 |
| mutation in microorganisms | /Salmonella typhimurium | 2.6 mmol/L/2H | MUREAV 578,225,2005 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 68.5 mg/L/16H | MUTAEX 20,105,2004 |
| mutation in microorganisms | /Salmonella typhimurium | 3 mg/L/2H (-enzymatic activation step) | MUREAV 578,210,2005 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 2 µmol/l | MUREAV 547,123,2004 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 316 µmol/L/6H | MUREAV 676,113,2009 |
| mutation in microorganisms | /Salmonella typhimurium | 1.87 mg/plate/48H | MUREAV 535,171,2003 |
| mutation in microorganisms | /Escherichia coli | 1.1 mmol/L/2H | MUREAV 535,171,2003 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 20 µmol/L/10M | MUREAV 673,53,2009 |
| mutation in microorganisms | /Salmonella typhimurium | 4 mmol/L | MUTAEX 22,293,2007 |
| mutation in microorganisms | /Salmonella typhimurium | 100 µg/plate/48H (-enzymatic activation step) | FCTOD7 50,3360,2012 |
| mutation in microorganisms | /Escherichia coli | 1.2 mmol/L/30M | MUREAV 714,11,2011 |
| mutation in microorganisms | /Saccharomyes cerevisiae | 4 mmol/L/1H | EMMUEG 48,728,2007 |
| mutation in microorganisms | /Salmonella typhimurium | 0.1 µmol/L/48H | EMMUEG 50,451,2009 |
| mutation in microorganisms | /Escherichia coli | 1 µg/L/2H (-enzymatic activation step) | FCTOD7 48,320,2010 |
| other mutation test systems | other cell types/human | 0.5 mmol/L/6H | MUREAV 648,15,2008 |
| other mutation test systems | /Escherichia coli | 100 µmol/L | MUREAV 203,81,1988 |
| other mutation test systems | /Salmonella typhimurium | 45 mg/L | MUREAV 192,239,1987 |
| other mutation test systems | /Bacillus subtilis | 100 µmol/L | MUREAV 4,517,1967 |
| other mutation test systems | other cell types/human | 1200 µmol/L | CNREA8 45,2522,1985 |
| phage inhibition capacity | /Escherichia coli | 500 ng/well | MUREAV 260,349,1991 |
| sister chromatid exchange | lung/hamster | 40 µmol/L | MUREAV 174,21,1986 |
| sister chromatid exchange | ovary/hamster | 80 µmol/L | MUREAV 224,269,1989 |
| sister chromatid exchange | ovary/hamster | 0.075 mmol/L/1H | MUREAV 649,114,2008 |
| sister chromatid exchange | /Saccharomyes cerevisiae | 0.04 pph | MUREAV 547,123,2004 |
| specific locus test | Ascites tumor/mouse | 5 mg/L/4H | EMMUEG 42,19,2003 |
| specific locus test | other cell types/mouse | 28 µmol/L/4H | MUREAV 678,123,2009 |
| specific locus test | ovary/hamster | 400 µmol/L/20M | MUREAV 602,14,2006 |
| specific locus test | /Escherichia coli | 50 µmol/L/30M | MUREAV 628,123,2007 |
| specific locus test | /Escherichia coli | 1 µmol/L/4H | MUREAV 560,27,2004 |
| specific locus test | kidney/mouse | 65 µmol/L | MUREAV 503,69,2002 |
| specific locus test | /Escherichia coli | 2.5 mmol/L/10M | MUREAV 508,107,2002 |
| specific locus test | oral/Drosophila melanogaster | 0.18 mole/L/4D-continuous | MUREAV 703,137,2010 |
| specific locus test | other cell types/human | 144000000 units/L | MUREAV 726,151,2011 |
| Unscheduled DNA Synthesis | fibroblast/human | 1 mmol/L | CALEDQ 5,199,1978 |
| Unscheduled DNA Synthesis | lung/human | 600 µg/L | ENMUDM 5,177,1983 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/mouse | lowest published toxic dose: 144 gm/kg/26W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Tumors | GANNA2 75,17,1984 |
| oral/mouse | toxic dose: 168 gm/kg/30W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Tumors | GANNA2 75,17,1984 |
| skin/mouse | lowest published toxic dose: 4032 mg/kg/18W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Skin and Appendages: Tumors Tumorigenic: Facilitates action of known carcinogens | ARTODN 78,139,2004 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Hamster, ovary | Inhibitor Concentration Low: 250 µmol/L | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 50,2729,2012 |
| In Vitro/Hamster, ovary | Inhibitor Concentration Low: 250 µmol/L | In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function | FCTOD7 50,2729,2012 |
| In Vitro/Human, blood (whole or unspecified cells) | Inhibitor Concentration Low: 400 µmol/L | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TXCYAC 278,242,2010 |
| In Vitro/Human, colon tumor | Inhibitor Concentration Low: 6 µmol/L/24H | In Vitro Toxicity Studies: Apoptosis in vitro | TXAPA9 246,116,2010 |
| In Vitro/Human, endothelium | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 50,3133,2012 |
| In Vitro/Human, endothelium | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro Biochemical: Metabolism (intermediary): Effect on mitochondrial function | FCTOD7 50,3133,2012 |
| In Vitro/Human, endothelium | Inhibitor Concentration Low: 200 µmol/L | In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro | FCTOD7 50,3133,2012 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 100 µmol/L/4H | In Vitro Toxicity Studies: Hemolysis in vitro In Vitro Toxicity Studies: Other assays | FCTOD7 49,2292,2011 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 3.3 mmol/L/2.5H | In Vitro Toxicity Studies: Hemolysis in vitro | FCTOD7 50,141,2012 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.9 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays | TXAPA9 250,130,2011 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.8 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXAPA9 250,130,2011 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.9 mmol/L/30M | In Vitro Toxicity Studies: Other assays | TXAPA9 250,130,2011 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 2 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TXCYAC 272,32,2010 |
| In Vitro/Human, lung | Inhibitor Concentration Low: 200 µmol/L/12H | Biochemical: Metabolism (intermediary): Effect on mitochondrial function | FCTOD7 50,2417,2012 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 100 µmol/L/10M | In Vitro Toxicity Studies: Other assays | FCTOD7 49,2292,2011 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 10 µmol/L/10M | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay In Vitro Toxicity Studies: Apoptosis in vitro | FCTOD7 49,2947,2011 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 500 µmol/L/120M | In Vitro Toxicity Studies: Other assays | FCTOD7 50,823,2012 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 30 pph/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 50,1001,2012 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 100 µmol/L/4H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays | NETOX* 32,518,2011 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 1 mmol/L/3H | In Vitro Toxicity Studies: Other assays | FCTOD7 50,1454,2012 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 50,1589,2012 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 50 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | FCTOD7 50,1841,2012 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 0.5 mmol/L/15M | In Vitro Toxicity Studies: Other assays | TXAPA9 246,66,2010 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 0.5 mmol/L/30M | Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TXAPA9 246,66,2010 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 1 mmol/L/16H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays | FCTOD7 50,492,2012 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 49,2780,2011 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 500 µmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | JOETD7 136,297,2011 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 500 µmol/L/30M | In Vitro Toxicity Studies: Other assays | JOETD7 136,297,2011 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 400 µmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro | FCTOD7 49,1011,2011 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 10 mmol/L/18H | In Vitro Toxicity Studies: Other assays | TXCYAC 271,83,2010 |
| In Vitro/jti | Inhibitor Concentration Low: 1 mmol/L/30M | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Peptidases | TXAPA9 244,315,2010 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration Low: 400 µmol/L/2H | In Vitro Toxicity Studies: Other assays | TXAPA9 246,91,2010 |
| In Vitro/Mouse, neuroblastom | Inhibitor Concentration Low: 2 mmol/L/10H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FTRPAE 83,223,2012 |
| In Vitro/paa | Inhibitor Concentration Low: 20 µmol/L/10M | Brain and Coverings: Recordings from specific areas of CNS In Vitro Toxicity Studies: Other assays | JOETD7 134,147,2011 |
| In Vitro/pda | Inhibitor Concentration Low: 300 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | FCTOD7 49,2131,2011 |
| In Vitro/pda | Inhibitor Concentration Low: 1 mmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 49,2131,2011 |
| In Vitro/pzx | Inhibitor Concentration Low: 10 mmol/L/2H | Nutritional and Gross Metabolic: Changes in: Other metals | TXCYAC 276,27,2010 |
| In Vitro/pzx | Inhibitor Concentration Low: 10 µmol/L/2H | In Vitro Toxicity Studies: Other assays | TXCYAC 276,27,2010 |
| In Vitro/Rat, endocrine tumor | Inhibitor Concentration Low: 200 µmol/L/4H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | JOETD7 134,275,2011 |
| In Vitro/Rat, endocrine tumor | Inhibitor Concentration Low: 50 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | NRTXDN 33,138,2012 |
| In Vitro/Rat, glioma | Inhibitor Concentration (50 percent kill): 143 µmol/L/24H | In Vitro Toxicity Studies: Cell protein synthesis | FCTOD7 49,2398,2011 |
| In Vitro/Rat, glioma | Inhibitor Concentration (50 percent kill): 686 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 49,2398,2011 |
| In Vitro/Rat, glioma | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell protein synthesis | FCTOD7 49,2398,2011 |
| In Vitro/Rat, liver | Inhibitor Concentration Low: 0.01 mmol/L | In Vitro Toxicity Studies: Other assays | TXCYAC 278,356,2010 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 0.214 mmol/L/24H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 18,79,2004 |
| In Vitro/Rat, neurons | Inhibitor Concentration Low: 120 µmol/L/10H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro | JOETD7 134,147,2011 |
| In Vitro/Rat, neurons | Inhibitor Concentration Low: 10 mmol/L/0.5M | Nutritional and Gross Metabolic: Changes in: Ca In Vitro Toxicity Studies: Other assays | JOETD7 134,147,2011 |
| In Vitro/Rat, neurons | Inhibitor Concentration Low: 25 µmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | FCTOD7 49,2862,2011 |
| In Vitro/Rat, neurons | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays | FCTOD7 49,2862,2011 |
| inhalation/human | lowest published toxic concentration: 10 mg/m3 | Skin: After topical application: Primary irritation | VCVN1* -,18,1998 |
| inhalation/human | lowest published toxic concentration: 20 mg/m3 | Peripheral Nerve and Sensation: Flaccid paralysis with appropriate anesthesia Behavioral: Tetany Cardiac: Arrythmias (indlucing changes in conduction) | VCVN1* -,18,1998 |
| inhalation/mammal (species unspecified) | lowest published toxic concentration: 60 mg/m3/4H | Skin: After topical application: Primary irritation | VCVN1* -,17,1998 |
| inhalation/mouse | Lowest published lethal concentration: 227 ppm | AEHLAU 4,327,1962 | |
| inhalation/rat | lethal concentration (50 percent kill): 2 gm/m3/4H | Lung, Thorax, or Respiration: Pulmonary emboli | GTPZAB 21(10),22,1977 |
| inhalation/rat | lethal concentration (50 percent kill): 2000 mg/m3 | VCVN1* -,17,1998 | |
| intraperitoneal/mouse | lethal dose (50 percent kill): 880 mg/kg | VCVN1* -,17,1998 | |
| intravenous/Dog | lowest published toxic dose: 0.003 mg/kg | Behavioral: Excitement Behavioral: Tetany Lung, Thorax, or Respiration: Dyspnea | VCVN1* -,17,1998 |
| intravenous/horse, donkey | lowest published toxic dose: 40 µg/kg | Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Dyspnea Gastrointestinal: Hypermotility, diarrhea | VCVN1* -,17,1998 |
| intravenous/rabbit | lowest published lethal dose: 0.004 mg/kg | Behavioral: Tremor Behavioral: Ataxia Lung, Thorax, or Respiration: Dyspnea | VCVN1* -,17,1998 |
| intravenous/rabbit | lethal dose (50 percent kill): 15 gm/kg | Behavioral: Convulsions or effect on seizure threshold | MRLR** #75,1951 |
| oral/mouse | lethal dose (50 percent kill): 2000 mg/kg | VCVN1* -,17,1998 | |
| oral/rat | lethal dose (50 percent kill): 4050 mg/kg | VCVN1* -,17,1998 | |
| oral/rat | lethal dose (50 percent kill): 376 mg/kg | Gastrointestinal: Peritonitis Blood: Pigmented or nucleated red blood cells Blood: Changes in leukocyte (WBC) count | STGNBT -,39,1999 |
| skin/mouse | lethal dose (50 percent kill): 1072 mg/kg | VCVN1* -,17,1998 | |
| skin/pig | lowest published lethal dose: 2 gm/kg | Behavioral: Convulsions or effect on seizure threshold | MRLR** #75,1951 |
| skin/rabbit | lowest published lethal dose: 500 mg/kg | Behavioral: Convulsions or effect on seizure threshold | MRLR** #75,1951 |
| skin/rat | lethal dose (50 percent kill): 4060 mg/kg | Lung, Thorax, or Respiration: Pulmonary emboli | GTPZAB 21(10),22,1977 |
| subcutaneous/mouse | lethal dose (50 percent kill): 1072 mg/kg | GISAAA 48(6),28,1983 | |
| subcutaneous/rat | lethal dose (50 percent kill): 620 mg/kg | VCVN1* -,17,1998 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/Dog | lowest published toxic concentration: 7 ppm/6H/26W- intermittent | Skin: After systemic exposure: Dermatitis, other Skin and Appendages: Other: Hair | AMIHBC 10,319,1954 |
| inhalation/mouse | lowest published toxic concentration: 57 ppm/6H/6W- intermittent | Skin: After systemic exposure: Dermatitis, irritative Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | AMIHBC 10,319,1954 |
| inhalation/rat | lowest published toxic concentration: 67 ppm/6H/6W- intermittent | Skin: After systemic exposure: Dermatitis, irritative Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | AMIHBC 10,319,1954 |
| inhalation/rat | lowest published toxic concentration: 10 mg/m3/5H/17W- intermittent | Lung, Thorax, or Respiration: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Monoamine oxidase Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases | GTPZAB 21(10),22,1977 |
| inhalation/rat | lowest published toxic concentration: 10 mg/m3/5H/8W- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | VCVN1* -,18,1998 |
| inhalation/rat | lowest published toxic concentration: 10 mg/m3/5H/17W- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects | VCVN1* -,18,1998 |
| intraperitoneal/non-mammalian species | lowest published toxic dose: 12 mg/kg/6D- intermittent | Liver: Other changes | TOXID9 66,67,2002 |
| intraperitoneal/rat | lowest published toxic dose: 1190.7 mg/kg/10W- intermittent | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | FCTOD7 50,1860,2012 |
| oral/rabbit | lowest published toxic dose: 8.75 mg/kg/25W- continuous | Endocrine: Effect on menstrual cycle Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVN1* -,19,1988 |
| oral/rat | lowest published toxic dose: 8.75 mg/kg/25W- continuous | Endocrine: Effect on menstrual cycle Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVN1* -,19,1988 |
| oral/rat | lowest published toxic dose: 1400 mg/kg/14D- intermittent | Cardiac: Other changes Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | FCTOD7 49,898,2011 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 1 ppm | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Confirmed animal carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMEMDT 36,285,1985 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMEMDT 71,671,1999 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 36,285,1985 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 71,671,1999 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 71,671,1999 |
| TOXICOLOGY REVIEW | MUREAV 566,99,2004 | |
| TOXICOLOGY REVIEW | MUREAV 544,179,2003 | |
| TOXICOLOGY REVIEW | TXAPA9 197,144,2004 | |
| TOXICOLOGY REVIEW | FCTOD7 44,301,2006 | |
| TOXICOLOGY REVIEW | MUTAEX 19,251,2004 | |
| TOXICOLOGY REVIEW | MUREAV 616,11,2007 | |
| TOXICOLOGY REVIEW | ENTOX* -,543,2005 | |
| TOXICOLOGY REVIEW | MUREAV 635,90,2007 | |
| TOXICOLOGY REVIEW | MUTAEX 19,3,2004 | |
| TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
| TOXICOLOGY REVIEW | MUREAV 533,65,2003 | |
| TOXICOLOGY REVIEW | MUREAV 533,133,2003 | |
| TOXICOLOGY REVIEW | MUREAV 533,183,2003 | |
| TOXICOLOGY REVIEW | MUTAEX 19,169,2004 | |
| TOXICOLOGY REVIEW | MUREAV 658,154,2008 | |
| TOXICOLOGY REVIEW | MUREAV 659,15,2008 | |
| TOXICOLOGY REVIEW | REPTED 25,291,2007 | |
| TOXICOLOGY REVIEW | MUREAV 657,84,2008 | |
| TOXICOLOGY REVIEW | HUTOX* -,683,1996 | |
| TOXICOLOGY REVIEW | MUREAV 672,1,2009 | |
| TOXICOLOGY REVIEW | MUREAV 543,191,2003 | |
| TOXICOLOGY REVIEW | MUREAV 681,3,2009 | |
| TOXICOLOGY REVIEW | BJMRDK 41,545,2008 | |
| TOXICOLOGY REVIEW | MUREAV 681,24,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,3,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,36,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,31,2009 | |
| TOXICOLOGY REVIEW | MUREAV 681,44,2009 | |
| TOXICOLOGY REVIEW | MUREAV 681,51,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,62,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,73,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,137,2009 | |
| TOXICOLOGY REVIEW | MUREAV 674,85,2009 | |
| TOXICOLOGY REVIEW | MUREAV 681,33,2009 | |
| TOXICOLOGY REVIEW | MUREAV 681,68,2009 | |
| TOXICOLOGY REVIEW | MUTAEX 17,529,2002 | |
| TOXICOLOGY REVIEW | MUTAEX 17,495,2002 | |
| TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
| TOXICOLOGY REVIEW | MUREAV 667,98,2009 | |
| TOXICOLOGY REVIEW | MUREAV 682,39,2009 | |
| TOXICOLOGY REVIEW | MUTAEX 22,161,2007 | |
| TOXICOLOGY REVIEW | MUTAEX 21,219,2006 | |
| TOXICOLOGY REVIEW | MUTAEX 21,225,2006 | |
| TOXICOLOGY REVIEW | MUREAV 579,6,2005 | |
| TOXICOLOGY REVIEW | MUREAV 669,8,2009 | |
| TOXICOLOGY REVIEW | MUREAV 682,94,2009 | |
| TOXICOLOGY REVIEW | MUTAEX 23,153,2008 | |
| TOXICOLOGY REVIEW | MUREAV 704,152,2010 | |
| TOXICOLOGY REVIEW | MUTAEX 23,271,2008 | |
| TOXICOLOGY REVIEW | TXAPA9 243,239,2010 | |
| TOXICOLOGY REVIEW | MUREAV 690,3,2010 | |
| TOXICOLOGY REVIEW | MUREAV 705,107,2010 | |
| TOXICOLOGY REVIEW | MUTAEX 24,383,2009 | |
| TOXICOLOGY REVIEW | MUTAEX 23,191,2008 | |
| TOXICOLOGY REVIEW | MUTAEX 26,101,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,231,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,69,2011 | |
| TOXICOLOGY REVIEW | MUREAV 685,3,2010 | |
| TOXICOLOGY REVIEW | MUREAV 727,1,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,193,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,51,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,199,2011 | |
| TOXICOLOGY REVIEW | MUREAV 711,13,2011 | |
| TOXICOLOGY REVIEW | MUREAV 711,158,2011 | |
| TOXICOLOGY REVIEW | MUREAV 728,47,2011 | |
| TOXICOLOGY REVIEW | MUREAV 717,54,2011 | |
| TOXICOLOGY REVIEW | MUREAV 750,60,2012 | |
| TOXICOLOGY REVIEW | MUREAV 26,253,2011 | |
| TOXICOLOGY REVIEW | MUREAV 728,35,2011 | |
| TOXICOLOGY REVIEW | MUREAV 728,12,2011 | |
| TOXICOLOGY REVIEW | MUREAV 750,107,2012 | |
| TOXICOLOGY REVIEW | REPTED 33,188,2012 | |
| TOXICOLOGY REVIEW | MUREAV 736,122,2012 | |
| TOXICOLOGY REVIEW | MUREAV 751,15,2012 | |
| TOXICOLOGY REVIEW | MUREAV 751,77,2012 | |
| TOXICOLOGY REVIEW | MUREAV 751,247,2012 | |
| TOXICOLOGY REVIEW | MUREAV 751,158,2012 | |
| TOXICOLOGY REVIEW | REPTED 35,165,2013 | |
| TOXICOLOGY REVIEW | MUREAV 752,25,2013 | |
| TOXICOLOGY REVIEW | MUREAV 733,4,2012 | |
| TOXICOLOGY REVIEW | MUREAV 752,61,2013 | |
| TOXICOLOGY REVIEW | MUTAEX 25,101,2010 | |
| TOXICOLOGY REVIEW | MUREAV 733,39,2012 | |
| TOXICOLOGY REVIEW | MUREAV 752,99,2013 | |
| TOXICOLOGY REVIEW | MUTAEX 25,101,2010 | |
| TOXICOLOGY REVIEW | MUREAV 752,72,2013 | |
| TOXICOLOGY REVIEW | NRTXDN 32,563,2011 | |
| TOXICOLOGY REVIEW | REPTED 34,298,2012 | |
| TOXICOLOGY REVIEW | MUREAV 752,153,2012 | |
| TOXICOLOGY REVIEW | MUTAEX 23,143,2008 | |
| TOXICOLOGY REVIEW | MUTAEX 23,171,2008 | |
| TOXICOLOGY REVIEW | MUREAV 743-744,67,2013 | |
| TOXICOLOGY REVIEW | MUREAV 751,158,2012 | |
| TOXICOLOGY REVIEW | EMMUEG 53,683,2012 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION | FEREAC 54,7740,1989 | |
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES | RED Completed | RBREV* -,330,1998 |
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 1 ppm (1.4 mg/m3) | DTLVS* 3,131,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 1 ppm (1.4 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 1 ppm (1.4 mg/m3);KZW 2 ppm (2.8 mg/m3), 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 1 ppm (1.4 mg/m3), MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 1 ppm (1.4 mg/m3), MAY2011 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 1 ppm (1.4 mg/m3), short term exposure limit 3 ppm (4.2 mg/m3), NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 1 ppm (1.5 mg/m3), FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 0.5 ppm (0.71 mg/m3), 2011 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 1 ppm (1.4 mg/m3), NOV2011 | |
| Occupational Exposure Limit-KOREA | time-weighted average 1 ppm (1.5 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 1 ppm (1.5 mg/m3);short term exposure limit 2 ppm (3 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 1 ppm (1.4 mg/m3), JAN2002 | |
| Occupational Exposure Limit-NORWAY | time-weighted average 1 ppm (1.4 mg/m3), JAN1999 | |
| Occupational Exposure Limit-PERU | time-weighted average 1 ppm (1,4 mg/m3), JUL2005 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 1 ppm (1.4 mg/m3), ceiling concentration 2 ppm (3 mg/m3), JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | ceiling concentration 0.5 ppm (0.71 mg/m3), JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 1.4 mg/m3, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 1 ppm (1.4 mg/m3), JAN1993 | |
| Occupational Exposure Limit-TURKEY | time-weighted average 1 ppm (1.4 mg/m3), JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 1 ppm (1.4 mg/m3);short term exposure limit 2 ppm (2.8 mg/m3), OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 1 ppm (1.4 mg/m3) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 1 ppm (1.4 mg/m3) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 1 ppm (1.4 mg/m3) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 1 ppm (1.4 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO HYDROGEN PEROXIDE-air | 10H time-weighted average 1.0 ppm | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 38605; Number of Industries 171; Total Number of Facilities 22930; Number of Occupations 142; Total Number of Employees Exposed 1006752; Total Number of Female Employees Exposed 727702 | |
| National Occupational Hazard Survey 1974 | Hazard Code 38605; Number of Industries 168; Total Number of Facilities 19597; Number of Occupations 83; Total Number of Employees Exposed 422227 |
Status in Federal Agencies
- Page last reviewed:March 7, 2014
- Page last updated:February 6, 2017
- Content source:
- National Institute for Occupational Safety and Health (NIOSH) Education and Information Division